High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer

F. Gutierrez-Delgado, L. A. Holmberg, H. Hooper, F. R. Appelbaum, Robert B Livingston, R. T. Maziarz, P. Weiden, S. Rivkin, P. Montgomery, K. Kawahara, W. Bensinger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease ≥ 10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. One hundred and twenty-one patients (median age, 46 years) were treated with high-dose Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) (HDC) followed by autologous stem cell infusion (ASCI). One hundred patients were initially treated with surgery followed by standard adjuvant chemotherapy prior to HDC/ASCI. Twenty-one patients with stage III disease had inoperable tumors at diagnosis and were treated with neoadjuvant chemotherapy and surgery before HDC/ASCI. Transplant-related mortality was 6%. The probabilities of event-free survival (EFS) at 3 and 5 years (median follow-up of 36 months) from transplant were, for all patients: 0.62-0.60; stage II: 0.71-0.67: stage III: 0.55-0.55 (for stage III adjuvant and neoadjuvant groups: 0.60-0.60 and 0.42-0.42, respectively). Multivariate analysis did not identify variables associated with poor outcome. The efficacy of Bu/Mel/TT is similar to other HDC regimens reported for patients with high-risk non-inflammatory breast cancer. Bu/Mel/TT has high activity in stage II disease and a moderate benefit in stage III operable tumors.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalBone Marrow Transplantation
Volume26
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Thiotepa
Busulfan
Melphalan
Breast Neoplasms
Stem Cells
Transplants
Adjuvant Chemotherapy
Disease-Free Survival
Neoplasms
Multivariate Analysis
Lymph Nodes
Drug Therapy
Mortality

Keywords

  • Breast cancer
  • Busulfan
  • High-dose chemotherapy
  • Melphalan
  • PBSC
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Gutierrez-Delgado, F., Holmberg, L. A., Hooper, H., Appelbaum, F. R., Livingston, R. B., Maziarz, R. T., ... Bensinger, W. (2000). High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer. Bone Marrow Transplantation, 26(1), 51-59.

High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer. / Gutierrez-Delgado, F.; Holmberg, L. A.; Hooper, H.; Appelbaum, F. R.; Livingston, Robert B; Maziarz, R. T.; Weiden, P.; Rivkin, S.; Montgomery, P.; Kawahara, K.; Bensinger, W.

In: Bone Marrow Transplantation, Vol. 26, No. 1, 2000, p. 51-59.

Research output: Contribution to journalArticle

Gutierrez-Delgado, F, Holmberg, LA, Hooper, H, Appelbaum, FR, Livingston, RB, Maziarz, RT, Weiden, P, Rivkin, S, Montgomery, P, Kawahara, K & Bensinger, W 2000, 'High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer', Bone Marrow Transplantation, vol. 26, no. 1, pp. 51-59.
Gutierrez-Delgado F, Holmberg LA, Hooper H, Appelbaum FR, Livingston RB, Maziarz RT et al. High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer. Bone Marrow Transplantation. 2000;26(1):51-59.
Gutierrez-Delgado, F. ; Holmberg, L. A. ; Hooper, H. ; Appelbaum, F. R. ; Livingston, Robert B ; Maziarz, R. T. ; Weiden, P. ; Rivkin, S. ; Montgomery, P. ; Kawahara, K. ; Bensinger, W. / High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer. In: Bone Marrow Transplantation. 2000 ; Vol. 26, No. 1. pp. 51-59.
@article{a22b582b06484c1a8a559a1c4b30aadb,
title = "High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer",
abstract = "The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease ≥ 10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. One hundred and twenty-one patients (median age, 46 years) were treated with high-dose Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) (HDC) followed by autologous stem cell infusion (ASCI). One hundred patients were initially treated with surgery followed by standard adjuvant chemotherapy prior to HDC/ASCI. Twenty-one patients with stage III disease had inoperable tumors at diagnosis and were treated with neoadjuvant chemotherapy and surgery before HDC/ASCI. Transplant-related mortality was 6{\%}. The probabilities of event-free survival (EFS) at 3 and 5 years (median follow-up of 36 months) from transplant were, for all patients: 0.62-0.60; stage II: 0.71-0.67: stage III: 0.55-0.55 (for stage III adjuvant and neoadjuvant groups: 0.60-0.60 and 0.42-0.42, respectively). Multivariate analysis did not identify variables associated with poor outcome. The efficacy of Bu/Mel/TT is similar to other HDC regimens reported for patients with high-risk non-inflammatory breast cancer. Bu/Mel/TT has high activity in stage II disease and a moderate benefit in stage III operable tumors.",
keywords = "Breast cancer, Busulfan, High-dose chemotherapy, Melphalan, PBSC, Thiotepa",
author = "F. Gutierrez-Delgado and Holmberg, {L. A.} and H. Hooper and Appelbaum, {F. R.} and Livingston, {Robert B} and Maziarz, {R. T.} and P. Weiden and S. Rivkin and P. Montgomery and K. Kawahara and W. Bensinger",
year = "2000",
language = "English (US)",
volume = "26",
pages = "51--59",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer

AU - Gutierrez-Delgado, F.

AU - Holmberg, L. A.

AU - Hooper, H.

AU - Appelbaum, F. R.

AU - Livingston, Robert B

AU - Maziarz, R. T.

AU - Weiden, P.

AU - Rivkin, S.

AU - Montgomery, P.

AU - Kawahara, K.

AU - Bensinger, W.

PY - 2000

Y1 - 2000

N2 - The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease ≥ 10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. One hundred and twenty-one patients (median age, 46 years) were treated with high-dose Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) (HDC) followed by autologous stem cell infusion (ASCI). One hundred patients were initially treated with surgery followed by standard adjuvant chemotherapy prior to HDC/ASCI. Twenty-one patients with stage III disease had inoperable tumors at diagnosis and were treated with neoadjuvant chemotherapy and surgery before HDC/ASCI. Transplant-related mortality was 6%. The probabilities of event-free survival (EFS) at 3 and 5 years (median follow-up of 36 months) from transplant were, for all patients: 0.62-0.60; stage II: 0.71-0.67: stage III: 0.55-0.55 (for stage III adjuvant and neoadjuvant groups: 0.60-0.60 and 0.42-0.42, respectively). Multivariate analysis did not identify variables associated with poor outcome. The efficacy of Bu/Mel/TT is similar to other HDC regimens reported for patients with high-risk non-inflammatory breast cancer. Bu/Mel/TT has high activity in stage II disease and a moderate benefit in stage III operable tumors.

AB - The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk non-inflammatory breast cancer defined as stage II disease ≥ 10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. One hundred and twenty-one patients (median age, 46 years) were treated with high-dose Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) (HDC) followed by autologous stem cell infusion (ASCI). One hundred patients were initially treated with surgery followed by standard adjuvant chemotherapy prior to HDC/ASCI. Twenty-one patients with stage III disease had inoperable tumors at diagnosis and were treated with neoadjuvant chemotherapy and surgery before HDC/ASCI. Transplant-related mortality was 6%. The probabilities of event-free survival (EFS) at 3 and 5 years (median follow-up of 36 months) from transplant were, for all patients: 0.62-0.60; stage II: 0.71-0.67: stage III: 0.55-0.55 (for stage III adjuvant and neoadjuvant groups: 0.60-0.60 and 0.42-0.42, respectively). Multivariate analysis did not identify variables associated with poor outcome. The efficacy of Bu/Mel/TT is similar to other HDC regimens reported for patients with high-risk non-inflammatory breast cancer. Bu/Mel/TT has high activity in stage II disease and a moderate benefit in stage III operable tumors.

KW - Breast cancer

KW - Busulfan

KW - High-dose chemotherapy

KW - Melphalan

KW - PBSC

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=0033924545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033924545&partnerID=8YFLogxK

M3 - Article

C2 - 10918405

AN - SCOPUS:0033924545

VL - 26

SP - 51

EP - 59

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -